MET and non-small cell lung carcinoma: Tepotinib, another oral selective MET TKI, in combination with osimertinib is still under investigation in the INSIGH2 trial (NCT03940703), a single-arm phase II study enrolling patients with advanced NSCLC with resistance to first- to third-generation EGFR-TKIs driven by MET amplification.63